Drugs / Numeta G16%E
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06842134 | Jan → May 2025 | — | Baxter Healthcare Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Numeta G16%E | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06842134 ↗ |
| Route | Intravenous | “will be given intravenously via peripherally inserted central catheter” NCT06842134 ↗ |